01/20/2006 08:50 FAX 7606033820

RECEIVED CENTRAL FAX CENTER

JAN 2 0 2006

PT0/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031

Hadaa ba Daa	secrets Reduction Art of 1806	L no namener am moutier	U.S.	Patent and Tr	rademark Office;	U.S. DEPARTMENT OF COMMERCE it displays a valid OMB control number.	
Under Inst Pag	Application	Application Number		ection of information unless it displays a valid OMB control number.			
TR	Filing Dat	Filing Date		1/14/2004			
	First Nam	First Named Inventor		Robert S. Andrews			
	Art Unit	Art Unit 1635					
(to be used for a	Examiner	Name	Tracy Ann	Tracy Ann Vivlemore			
		Docket Number	ISIS0038-1	ISIS0038-100 (CHEM0001US)			
Total Number of Peges in This Submission 8 Siccessive (c. 12.1165)							
ENCLOSURES (Check all that apply)							
Fee Trans	millal Form	Drawing(s)			After After	Allowance Communication to TC	
☐ Fe	e Attached	Licensing-re	icensing-related Papers			eal Communication to Board peals and Interferences	
Amendme	Petition	Pelition			eal Communication to TC eal Notice, Brief, Reply Brief)		
Amendine	Petition to C	Petition to Convert to a Provisional Application			rietary Information		
	Power of Att	Power of Attorney, Revocation Change of Correspondence Address			is Letter		
					Other Enclosure(s) (please identify		
Extension	Terminal Dis			below	N):		
Express A	Request for	Refund					
Informatio	n Disclosure Statement	CD, Numbe	r of CD(s)]		
Landscape Table on CD							
Certified Copy of Priority Document(s) Remarks							
Reply to Missing Parts/							
L_ Incomplete Application							
Reply to Missing Parts under 37 CFR 1.52 or 1.53							
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm Name Isis Pharmaceuticals, Inc.							
Signature Robert S. Onhews							
Printed name Robert S. Andrews							
Date	ate 1-20-06 Reg.				eg. No. 44,508		
	C	ERTIFICATE OF	TRANSMISE	BION/MAI	LING	- Address	
I hereby certify the sufficient postage the date shown be	as first class mall in an en	peing facsimile transmivelope addressed to:	itted to the USP Commissioner fo	TO or depos or Patents, F	ited with the UP.O. Box 1450	Inited States Postal Service with , Alexandria, VA 22313-1450 on	
Signature Mula Cerro							
Typed or printed n	ame Laura Earnes				Date	1/20/04	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or auggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

2002/008

Attorney Docket No: ISIS0038-100/CHEM0001US

Serial No. 10/757,298

January 20, 2006 Response to September 23, 2005 Action

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

In re application of: Andrews et al.

Group Art Unit:

1635

JAN 2 0 2006

Examiner:

Tracy Ann Vivlemore

Serial No.:

10/757,298

Confirmation No.:

5625

Filed:

Jan. 14, 2004

Docket No.:

ISIS0038-100

(CHEM0001US)

For:

MODIFIED OLIGONUCLEOTIDES FOR USE IN GENE

MODULATION

Certificate of Facsimile Transmission
I hereby certify that this paper is being facsimile transmitted to the Patent and Tradernark Office to facsimile number 571-293-8300 on: 1/20/00

Mail Stop: Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT AND REQUEST FOR RECONSIDERATION UNDER 37 CFR § 1.111

In response to the Office Action mailed on September 23, 2005, please amend the above-identified application as follows:

Listing of Claims, reflecting current amendments, begins on page 2 of this paper.

Remarks begin on page 5 of this paper.